Portfolio

  • READ MORE
    ADC Therapeutics
    ADC Therapeutics is focused on the development of proprietary Antibody Drug Conjugates for the treatment of both solid and hematological cancers.
    Visit website
  • READ MORE
    Auven Therapeutics
    Auven Therapeutics is a private equity firm pursuing an innovative life science investment strategy.
    Visit website
  • READ MORE
    BioPharma
    BioPharma has built a portfolio of debt securities and that are collateralized by royalties on drug sales.
    Visit website
  • READ MORE
    Bridge
    Bridge Pharma was a privately held research and development company focusing exclusively on pharmaceutical projects with blockbuster potential.
    Visit website
  • READ MORE
    Cibus
    Cibus produces environmentally-friendly crop traits for the agricultural community that do not carry the market-resistance or regulatory burden of the introduction of foreign genetic material.
    Visit website
  • READ MORE
    Cross Match Technologies
    CrossMatch Technologies is a leading provider of biometric identity management systems, applications and services.
    Visit website
  • READ MORE
    DeepBiome Therapeutics, Inc
    DeepBiome is building a drug discovery platform, applying leading research from top institutions to lower the time and cost barrier of drug discovery with its fast and cost-effective next generation technology. The DeepBiome platform combines artificial intelligence and synthetic biology to rapidly identify potential drug candidates which already exist in the human microbiome. DeepBiome already has proof of concept for IBD to a big pharma partner, the development was under 3 months, a fraction of the time to identify candidate compounds using traditional methods.
    Visit website
  • READ MORE
    DestinationRX
    DRX is the leading provider of technology solutions for web-based prescription drug comparison as well as Medicare health plan comparison and enrollment services.
    Visit website
  • READ MORE
    Enterin, Inc.
    Enterin is pioneering the medical community’s understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut, and the early onset and chronic progression of neurodegenerative disease.
    Visit website
  • READ MORE
    eReceivables
    eReceivables is a specialty servicer for healthcare receivables and the first company to have created and commercialized a standardized electronic system to process and appeal post-adjudicated disputed healthcare claims.
    Visit website
  • READ MORE
    FibroGen, Inc.
    FibroGen is a research-based biotechnology company formed to discover, develop, and commercialize novel therapeutics.
    Visit website
  • READ MORE
    GeneNews
    GeneNews offers a suite of differentiated molecular diagnostic tests that rely on a convenient in-office blood draw to find cancers of the colon, lung, breast and prostate, early.
    Visit website
  • READ MORE
    Intra-Cellular Therapies
    Intra-Cellular Therapies is a biopharmaceutical company focused on the discovery and clinical development of innovative, small molecule drugs.
    Visit website
  • READ MORE
    Klox Technologies
    Klox Technologies is a specialty pharmaceutical company focusing on the development and commercialization of its proprietary BioPhotonic technology platform.
    Visit website
  • READ MORE
    Koltan
    Kolltan Pharmaceuticals discovers and develops novel antibody-based drugs for the treatment of cancer and other diseases.
    Visit website
  • READ MORE
    LiquiGlide
    LiquiGlide is the first and only company to create permanently wet slippery surfaces.
    Visit website
  • READ MORE
    Mission Bay
    Mission Bay Capital is a venture firm focused on making pivotal, early-stage investments in bioscience companies.
    Visit website
  • READ MORE
    PayEase
    PayEase is China’s foremost payment service, providing comprehensive payment services via various channels.
    Visit website
  • READ MORE
    Rose
    ROSE-010 is used for the treatment of severe break-through pain associated with Irritable Bowel Syndrome (“IBS”). ROSE-010 has successfully completed two phase 2a trials that showed significant pain relief compared to placebo. IBS is a large indication with few good treatment options for break-through pain episodes. In a meaningful number of cases, patients use opioids to manage pain, which, in addition to the risk of addiction, can cause constipation and exacerbate gastrointestinal issues for IBS sufferers.
    Visit website
  • READ MORE
    Royalty Pharma
    Royalty Pharma is the industry leader in acquiring royalty interests in marketed and late stage biopharmaceutical products, with total assets of over $12 billion in over 40 products.
    Visit website
  • READ MORE
    Royalty Pharma Select
    Royalty Pharma Select represents an investment in an existing diversified portfolio of leading pharmaceutical and biopharmaceutical products without the risks and infrastructure costs associated with the development and commercialization of such products.
    Visit website
  • READ MORE
    Sprout
    Sprout produces a non-hormonal prescription pill used to treat Hypoactive Sexual Desire Disorder in women.
    Visit website
  • READ MORE
    Transparency Life Sciences
    Transparency Life Sciences is the first all-digital clinical development services company. TLS’s approach combines crowdsourcing and mobile health technology to advance drug candidates through clinical trials with unprecedented efficiency and patient and regulatory relevance.
    Visit website
  • READ MORE
    Warm Health Inc.
    Warm Health, Inc. provides technology enabled communication programs that enable health care organizations to engage, educate, motivate, and monitor their members, patients, and consumers.
    Visit website
  • READ MORE
    X-Vax
    X-Vax Technology is developing a novel vaccine for both the prophylaxis and treatment of herpes simplex virus Type 1 and Type 2 in adults and children. The vaccine candidate was developed in a research laboratory at the Albert Einstein College of Medicine and has been used to characterize the immune response in animals which differs from that of former herpes simplex vaccine candidates. The vaccine confers “sterilizing immunity” with rapid viral clearance and protection from latency in a range of animal models following challenge with a wide range of virulent clinical isolates.
    Visit website